PREVIOUS
✖
Molnupiravir
October 6 , 2021
1178 days
808
0
- Molnupiravir has reduced the chances of hospitalisation by half among COVID-19 patients with mild or moderate symptoms.
- This is according to the pharmaceutical company “Merck and Ridgeback Biotherapeutics”
- Molnupiravir drug has been named as ‘EIDD 2801’ by the company.
- Here ‘E’ indicates it was developed at Emory University of USA.
- The antiviral drugs work by inhibiting a process by which the virus replicates.
Leave a Reply
Your Comment is awaiting moderation.